Clinical-scale manufacturing of transposon-based CAR-T cells using next-generation electroporation 

Treating solid tumors with CAR-T cell therapy remains difficult, but with the advent of novel vector systems, such as transposons, coupled with tools like CRISPR/Cas9, researchers are making meaningful progress. This webinar examines how large-volume electroporation can support the reliable delivery of diverse clinically relevant cargo types, including DNA, mRNA, and CRISPR/Cas9 RNPs into large volumes of T cells.

Focusing on the next-generation 4D-Nucleofector® LV Unit PRO, the session will present case study examples showing how parameters optimized at small scale can be translated to clinical-scale manufacturing. Attendees will gain insight into how robust, GMP-aligned electroporation workflows enable efficient modification of up to one billion T cells, supporting knock-out, knock-in, and stable gene integration strategies for CAR-T development.

Attendees will learn:

• How a large-volume electroporation platform for delivery of clinically relevant cargos for CAR-T development and GMP manufacturing allows for versatility in terms of process parameters, starting material, and cargo type
• How to achieve reliable, robust, and efficient delivery of different cargo types like DNA and mRNA to complex, clinically relevant cargos for CRISPR knock-out/ knock-in (RNPs) and transposon-based integration
• Why transposons are cost-effective and scalable non-viral gene editing solutions that provide safer integration profiles

Register to learn how the electroporation of clinically relevant cargos using transposon-based integration methods into large volumes of T cells holds significant promise for applications in the CGT space. 

Shigeki Yagyu, PhD

Professor at Shinshu University

Shigeki Yagyu is a Professor at Shinshu University. He leads a basic and translational research laboratory focused on developing novel cell and gene therapies for hematologic and solid malignancies.

Stefanie Muthel, PhD

R&D Team Lead at Lonza Cologne

Stefanie Muethel is the R&D Team Lead at Lonza, where she and her team focus on optimizing gene editing technologies such as CRISPR/Cas9 and transposon-based integration for large-scale transfection.

In 31 Days

You have registered for this webinar

Register

SPEAKERS

Shigeki Yagyu, PhD

Professor at Shinshu University

Stefanie Muthel, PhD

R&D Team Lead at Lonza Cologne

You might also like

Combining CRISPR and transposon-based technologies for improved sdAb-based CAR-T therapies

Begoña Diez Cabezas, Juan Roberto Rodriguez-Madoz

17 June 2025

Watch

Non-viral, large-scale delivery of gene editing tools for T cell manufacturing

Stefanie Müthel, Andrea Toell

18 September 2025

Watch

Enabling scalable CAR-T therapies with next-gen animal component-free T cell media

Pedro Azevedo Da Silva Couto, Rukmini Ladi

17 September 2025

Watch

Commercialization of CAR-T therapy in New Zealand: clinical insights & scalable manufacturing

Tamara Laskowski, Laurence Cooper

12 August 2025

Watch